Trial Condition(s):

Renal Artery Stenosis

Magnevist® Injection-enhanced MRA compared to non contrast MRA for the detection of stenosis of the renal arteries

Bayer Identifier:

90940

ClinicalTrials.gov Identifier:

NCT00310557

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the renal arteries. The results will be compared to the results of MRI taken without Magnevist and with the results of your X-ray angiography.

Inclusion Criteria
- Has known or suspected renal artery disease - Is scheduled for X-ray angiography
Exclusion Criteria
- Has any contraindication to magnetic resonance imaging - Is scheduled for any procedure before the X-ray angiography  - Had previously had stents placed bilaterally in the region to be imaged

Trial Summary

Enrollment Goal
116
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design